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A potent trifluoromethyl ketone histone deacetylase
inhibitor exhibits class-dependent mechanism of
action
Andreas S. Madsen and Christian A. Olsen*
Histone deacetylase (HDAC) enzymes are validated targets for treatment of certain cancers and have po-
tential as targets for pharmacological intervention in a number of other diseases. Thus, inhibitors of these
enzymes have received considerable attention, but these are often evaluated by IC50 value determination,
which may vary significantly depending on assay conditions. In this work, we therefore performed detailed
kinetic evaluation of inhibitors containing two fundamentally different zinc-binding chemotypes, hydro-
xamic acid or trifluoromethyl ketone. For the hydroxamic acids, a fast-on–fast-off mechanism was ob-
served, but the trifluoromethyl ketone compound exhibited differential mechanisms depending on the en-
zyme isoform. The trifluoromethyl ketone compound displayed a fast-on–fast-off mechanism against
class-IIa HDACs 4 and 7, but slow-binding mechanisms against class-I and class-IIb enzymes (HDACs 1–3,
6 and 8). Furthermore, different competitive, slow-binding mechanisms were observed for HDACs 1, 2, and
6 vs. HDACs 3 and 8, demonstrating the power of kinetic experiments for characterisation of enzyme
inhibitors.
Introduction
The Zn2+-dependent histone deacetylase (HDAC) enzymes ca-
talyse hydrolytic removal of acetyl functionalities from
ε-amino groups of lysine residues in a variety of proteins in-
cluding histones.1 Posttranslational modification (PTM) plays
major roles in regulation of protein function, and histone
acetylation affects chromatin packing and recruitment of
transcription factors resulting in effects on gene expression.2,3
Recent discoveries have underpinned lysine acetylation as a
general PTM in proteins,4 and a growing list of non-histone
proteins are identified as substrates for the HDACs,5–8 thereby
extending their potential impact on cellular function.2,3,9,10
Eleven HDAC isoforms are encoded by the human genome,
classified according to sequence similarity:11 class-I (HDACs
1–3 and 8), class-IIa (HDACs 4, 5, 7 and 9), class-IIb (HDACs 6
and 10), and class-IV (HDAC11).
Due to the importance of HDACs in a wide variety of dis-
ease states,12–15 selective HDAC inhibitors have potential as
tool compounds and possibly as novel drugs. Several
chemotypes have been described as HDAC inhibitors with
the most extensively studied class being inhibitors featuring
the strongly zinc-chelating hydroxamic acid moiety,16,17 in-
cluding vorinostat (SAHA, 1) and trichostatin A (2) (Fig. 1).
Due to the strong metal ion-chelating propensity of hydro-
xamic acids, inhibitors containing this functionality have
been suspected to give rise to off-target effects, but recent ex-
periments have indicated that this may be of minor con-
cern.18,19 Nevertheless, hydroxamic acids have also been asso-
ciated with rapid degradation and clearance, and investigation
of other zinc-binding functionalities, such as thiols (as in
romidepsin (3)),20 trifluoromethyl ketones (4),21–24 and
o-aminoanilides (5)25,26 (Fig. 1), may therefore be of interest.
The binding mode of hydroxamic acids, which are gener-
ally considered potent class-I, -IIb and -IV inhibitors, but
much poorer class-IIa inhibitors,27 is through bidentate coor-
dination to the active site Zn2+ ion via the carbonyl oxygen
and deprotonated nitrogen-bound oxygen atom.28
Trifluoromethyl ketones constitute another strongly zinc-
binding functionality. This motif is readily hydrated in aque-
ous solution29 and presumably binds to the active site Zn2+
ion via bidentate coordination from the two resulting gemi-
nal hydroxy groups.30 Although trifluoromethyl ketones have
also been reported to be metabolically labile by reduction to
the corresponding alcohol in vivo,21 they may give rise to
interesting tool compounds for investigation of HDAC inhibi-
tion in vitro. Interestingly, compounds containing this zinc-
binding group have been reported to selectively inhibit class-
IIa HDAC isoforms;22,23,31 however, class-IIa inhibition does
not appear to be an inherent capacity of the functional group
itself.32 We recently reinvestigated the inhibitory properties
of a known trifluoromethyl ketone compound (4)21 and
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extended the previous studies to characterization of its
inhibitory effect against all eleven zinc-dependent HDACs,32
thereby identifying compound 4 as a promising inhibitor of
isozymes from all four HDAC classes.32 In our previous
study, IC50 and Ki values were determined from standard
endpoint dose–response assays assuming a fast-on–fast-off
binding mechanism. In these experiments, the HDAC
enzyme and fluorogenic substrate are incubated with vary-
ing concentrations of inhibitor for 1 h, followed by assay de-
velopment by addition of trypsin to achieve fluorophore re-
lease. Thus, a constant rate over the entire incubation
period has to be assumed in order to apply the Cheng–
Prusoff equation for approximation of the corresponding Ki
values.
While endpoint assays are convenient for screening large
numbers of inhibitors, more information can be obtained
from kinetic inhibition experiments, where progression of en-
zyme activity is monitored over time. By applying such assays,
Gottesfeld and co-workers demonstrated that pimelic
diphenylamide 106 (5), an o-aminoanilide based class-I HDAC
inhibitor, inhibits HDACs 1–3 via different mechanisms not
revealed by simple IC50 determination. They were instead
able to show that compound 5 is a slow, tight-binding inhibi-
tor of HDACs 1–3, but acting via a different mechanism for
HDACs 1 and 2 compared to HDAC3.26 More recently, two
groups have also reported on the development of kinetically
selective HDAC2 inhibitors based on o-aminoanilide moieties,
and considering differences in the active sites of HDACs
1–3.33,34
Interestingly, trifluoromethyl ketones have previously been
described as slow-binding inhibitors for serine prote-
ases,29,35,36 and we therefore found it interesting to perform
a more elaborate investigation of the inhibitory mechanism
of compound 4 on the different HDAC isoforms. We have
previously used continuous rate experiments for investigating
inhibitors of the NAD+-dependent deacylase sirtuin 537 as
well as cyclic peptide HDAC inhibitors38 and thought we
could modify those protocols for evaluation of compound 4
in continuous assays against a selection of the zinc-
dependent HDACs.
Not surprisingly, our investigation showed that the
hydroxamic acid-containing inhibitors acted via a fast-on–
fast-off binding mechanism against all the tested enzymes.
For the trifluoromethyl ketone inhibitor, on the other hand,
the mechanism of inhibition proved to vary between enzyme
isoforms. Thus, this study provides valuable mechanistic in-
sight for future medicinal chemistry efforts involving HDAC
inhibitors containing this zinc-binding group.
Results and discussion
Initially, we investigated the influence of preincubation of
HDAC3 and trifluoromethyl ketone 4 on the determined IC50
values and found a 17-fold increase in apparent inhibitor po-
tency at 2 h of preincubation time (Fig. 2). Further incuba-
tion lead to substantial decrease in enzyme activity, even
without addition of inhibitor, thus precluding prolonged
preincubation due to enzyme degradation in the assay buffer.
This initial observation prompted us to investigate the kinet-
ics of HDAC inhibition in more detail.
Usually, the equilibrium of inhibitor binding to enzyme is
assumed to be rapidly obtained, i.e., fast on and off rates for
the enzyme–inhibitor equilibrium, which is therefore
obtained prior to onset of the experiment. For this fast-on–
fast-off mechanism, linear progression curves are observed
when monitoring product formation continuously, and the
enzyme–inhibitor equilibrium constant (Ki) can be deter-
mined by fitting a secondary plot of the relative rates (vi/vo)
to eqn (1), where vi and vo are the observed rates with and
without inhibitor, respectively.
Fig. 1 Structures of selected HDAC inhibitors.
Fig. 2 Residual activity of HDAC3 after preincubation with
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(1)
However, if the enzyme–inhibitor equilibrium is slow and
thus not obtained prior to onset of the experiment, non-
linear progression curves will be obtained. In such an event,
the slow, competitive binding of inhibitor may be divided
into two mechanisms as shown in Fig. 3. In mechanism A,
the enzyme–inhibitor complex forms without kinetically ob-
servable intermediates, whereas in mechanism B, an equilib-
rium is rapidly established with an initial complex, which is
then converted to a second stable complex displaying rate-
determining kinetics.
For both types of slow binding kinetics, product formation
follows eqn (2), where [P] is the concentration of product at
time t. The vo and vs are the initial and final steady-state veloc-
ities, respectively, and kobs is the apparent first-order rate con-
stant for establishment of the enzyme–inhibitor equilibrium. It
should be noted, that for the fast-on–fast-off mechanism, [P] =
vst is the limiting case of mechanism A when kobs is very large.
(2)
For mechanisms A and B, the relationship between kobs
and [I] is linear (eqn (3)) and hyperbolic (eqn (4)), respec-
tively. As a result, fitting of these equations to secondary
plots of the kobs–[I] relationship allows determination of the
binding mechanism, as well as calculation of the rate con-
stants involved and the resulting enzyme–inhibitor equilib-
rium constants [Ki for mechanism A (eqn (5)) and Ki,1 and Ki
for mechanism B (eqn (6) and (7), respectively)].
Slow binding, mechanism A
(3)
(5)




To determine the inhibitory mechanism and associated ki-
netic values, we initially established assay conditions that
allowed monitoring of enzyme activity for 60 min. Progres-
sion curves were generated by incubating the enzyme–inhibi-
tor combination with an appropriate fluorogenic substrate at
concentrations greater than the Km [Ac-LGKac-AMC (20 μM)
for HDACs 1–3 and 6 (Km values 6 μM, 3 μM, 6 μM, and 16
μM, respectively), Ac-LGKtfa-AMC (50 μM) for HDACs 4 and 7
(Km values 12 μM and 26 μM, respectively), and Ac-RHKacKac-
AMC (400 μM) for HDAC8 (Km value 430 μM)]. The trypsin
concentration was optimised to be high enough to ensure
rapid establishment of steady state by cleaving the AMC
fluorophore from the deacylated peptide intermediate at a
rate that avoids lag time. At the same time, the trypsin con-
centration should be low enough to ensure a linear progress
curve for 60 min without observable reduction of HDAC activ-
ity in the experiment without inhibitor added. Previously,
Gottesfeld and co-workers reported low stability of HDAC8
under the employed conditions.26 In agreement with this, we
also observed rapid loss of activity of HDAC8 when incubated
in the standard Tris buffer. However, changing the buffer to
either the buffer marketed for HDAC8 (a Tris buffer
containing PEG8kDa) or the buffer described by Bradner,
Mazitschek and co-workers (a HEPES buffer, data not
shown),27 allowed monitoring of HDAC8 activity for 60 min
as well.
Having established suitable conditions for all the investi-
gated enzymes, a series of progress curves were generated for
HDACs 1–4 and 6–8 against the three investigated inhibitors
(1, 2 and 4).
SAHA (1) has previously been demonstrated to be a poor
class-IIa inhibitor32 and was not included for HDACs 4 and 7.
Instead, TSA was chosen as the hydroxamic acid inhibitor
against class-IIa HDACs and HDAC3 was chosen as the repre-
sentative for TSA inhibition of class-I HDACs. All seven
HDACs were included for investigation of compound 4.
Hydroxamate inhibitors such as SAHA have been reported
to display fast-on–fast-off kinetics against class-I HDACs,26
and in agreement with these reports, linear progress curves
were obtained for inhibition of HDACs 1–3 and 8 as well as
the class-IIb enzyme HDAC6 when monitored for 1 h (Fig. 4).
Low nanomolar inhibition constants were observed for all in-
vestigated enzymes except for HDAC8 (230 ± 20 nM; Table 1),
and all values are in agreement with the literature.27 Simi-
larly, linear progress curves were obtained for TSA inhibition
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of all investigated enzymes, including class-IIa enzymes
HDAC4 and HDAC7 (Fig. 4). Despite a marked span of poten-
cies of almost 2000-fold (0.54 ± 0.02 nM vs. 980 ± 80 nM for
HDACs 3 and 4, respectively), these results indicate that fast-
on–fast-off kinetics is general for hydroxamate mediated
HDAC inhibition regardless of enzyme class and potency.
Interestingly, trifluoromethyl ketone 4 displayed a differ-
ential inhibition mechanism depending on enzyme class.
Thus compound 4 was found to be a potent inhibitor of
class-IIa enzymes displaying a fast-on–fast-off mechanism
with Ki values of 5.1 ± 0.2 nM and 4.7 ± 0.1 nM against
HDACs 4 and 7, respectively (Fig. 5).
In contrast, compound 4 displayed slow binding kinetics
with non-linear progression curves when incubated with all
the investigated class-I and class-IIb enzymes. The obtained
progression curves were fitted to eqn (2) and secondary plots
of the calculated kobs values against inhibitor concentration
were created (Fig. 5). For HDACs 1, 2 and 6, a linear relation-
ship was observed, consistent with competitive, slow-binding
of the inhibitor following mechanism A, and the data were
therefore fitted to eqn (3) to determine the kinetic parame-
ters. The overall inhibition constants (Ki) were determined to
be 9.8 μM, 11 μM and 4.5 μM, respectively. For HDACs 1 and
6, these are in good agreement with our previous findings
using endpoint experiments, while the Ki value against
HDAC2 is ∼30-fold higher than the previously determined.32
The overall trend that HDACs 4 and 7 are significantly more
potently inhibited than HDACs 1, 2 and 6, however, corre-
sponds well with previous findings.
For HDACs 3 and 8, on the other hand, a hyperbolic rela-
tionship between kobs and inhibitor concentration was indi-
cated, which is consistent with competitive, slow binding of
the inhibitor following mechanism B. Thus, fitting of the
data to eqn (4) allowed determination of the accompanying
kinetic parameters (Table 2). For HDAC3 the overall inhibi-
tion constant (Ki) was estimated to be 11 nM and the overall
inhibition constant (Ki) for HDAC8 was estimated to be 33
nM, which is in the range of inhibition constants for class-IIa
HDACs 4 and 7. For HDAC3, the Ki value is an order of mag-
nitude lower than previously estimated from endpoint experi-
ments using the Cheng–Prusoff equation,32 which may be
explained by a low k−2 value indicating a highly stable en-
zyme–inhibitor complex (E:I*, Fig. 3 mechanism B). This also
helps explain the data obtained by preincubation experi-
ments discussed above (Fig. 2), and underlines the power of
kinetic evaluation of inhibitors that do not follow standard
fast-on–fast-off mechanism of action.
Interestingly, potent inhibition of HDACs 3, 4, 7 and 8 by
trifluoromethyl ketone 4 correlates well with the observation
that these enzymes all efficiently cleave ε-N-trifluoroacetylated
lysine substrates.39 Furthermore, the lower affinities for com-
pound 4 against HDACs 1, 2 and 6 also agree with the low
detrifluoroacetylase activities of these enzymes. Taken together,
these observations suggest that certain HDACs accommodate
the trifluoromethyl group better than others, and that this fea-
ture is not in accordance with isoform sub-classification.
Conclusions
In summary, we have evaluated hydroxamate and trifluoromethyl
ketone HDAC inhibitors by continuous assays monitoring the
progress of substrate conversion over time to enable kinetic in-
sight. We selected enzymes from class-I (HDACs 1–3 and 8),
class-IIa (HDACs 4 and 7), and class-IIb (HDAC6), and as
Table 1 Ki values (nM) for HDAC inhibition by SAHA (1) and TSA (2)
HDAC1 HDAC2 HDAC3 HDAC8 HDAC6 HDAC4 HDAC7
1 6.4 ± 0.2 4.2 ± 0.1 9.9 ± 0.3 230 ± 20 17.7 ± 0.3 n.d. n.d.
2 n.d. n.d. 0.54 ± 0.02 200 ± 20 n.d. 980 ± 80 300 ± 10
Fig. 4 Progress curves of HDAC1 (LGKac) and HDAC4 (LGKtfa) deacylase
activities under SAHA and TSA inhibition, respectively. Relative rates (vi/vo),
fitted to eqn (1), for HDACs 1–3 and 6 (LGKac), and HDAC8 (RHKacKac)
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Fig. 5 Progress curves of HDACs 1–3 and 6 (LGKac), HDAC8 (RHKacKac), and HDACs 4 and 7 (LGKtfa) deacylase activities under inhibition by
trifluoromethyl ketone 4. Apparent first-order rate constants (kobs) for trifluoromethyl ketone 4 inhibition were fitted to eqn (3) for HDACs 1, 2 and
6 (LGKac) or eqn (4) for HDAC3 and relative rates (vi/vo) were fitted to eqn (1) for HDACs 4 and 7.
Table 2 Kinetic values and inhibition constants for HDAC inhibition by trifluoromethyl ketone 4
HDAC1 HDAC2 HDAC3 HDAC8 HDAC6 HDAC4 HDAC7
Ki (nM) (9.8 ± 6.7) × 10
3 (1.1 ± 0.4) × 104 ∼11 ∼33 (4.5 ± 1.6) × 103 5.1 ± 0.2 4.7 ± 0.1
k1 (M
−1 min−1) (1.7 ± 0.4) × 103 (7.7 ± 0.8) × 102 — — (2.6 ± 0.3) × 103 — —
k−1 (min
−1) (1.7 ± 0.7) × 10−2 (8 ± 2) × 10−3 — — (1.2 ± 0.3) × 10−2 — —
Ki,1 (nM) — — (5.7 ± 2.6) × 10
2 (7.3 ± 5.7) × 103 — — —
k2 (min
−1) — — 0.24 ± 0.03 0.49 ± 0.13 — — —
k−2 (min
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suspected based on literature precedent, the hydroxamic acids
all exhibited a fast-on–fast-off mechanism of inhibition. How-
ever, the SAHA-inspired trifluoromethyl ketone (4) only displayed
a fast-on–fast-off mechanism against HDACs 4 and 7, whereas
slow-binding mechanisms were observed against class-I and
class-IIb enzymes (HDACs 1–3, 6 and 8). Furthermore, a more
detailed investigation revealed similar mechanisms for HDACs 1,
2, and 6, which were different from the mechanism exhibited
against HDACs 3 and 8. This insight is important for under-
standing the effects of trifluoromethyl ketone containing inhibi-
tors, and should be taken into account when designing novel
chemotypes containing this moiety. Furthermore, it will be inter-
esting to investigate the possible effects of these mechanistic dif-




HDAC1, HDAC2, HDAC3–NCoR1, HDAC6 and HDAC8 were
purchased from Enzo Life Sciences (Postfach, Switzerland).
HDAC4 and HDAC7 were purchased from Millipore (Upstate,
Temecula, CA). The HDAC assay buffers used were: Buffer A,
Biomol International BML-KI-143 [Tris/Cl (50 mM), NaCl (137
μM), KCl (2.7 μM), MgCl2 (1 μM), pH 8.0] with BSA (0.5 mg
mL−1) added; or Buffer B, Biomol International BML-KI-311
[Tris/Cl (50 mM), NaCl (137 μM), KCl (2.7 μM), MgCl2 (1 μM),
PEG-8 kDa (10% w/v), pH 8.0] with BSA (0.5 mg mL−1) added.
Trichostatin A and trypsin (10 000 units per mg, TPCK treated
from bovine pancreas) were from Sigma-Aldrich (Steinheim,
Germany), and syntheses of SAHA and compound 4 were pre-
viously reported.32 All chemicals and solvents were of analyti-
cal grade and were used without further purification as
obtained from commercial suppliers.
Fluorescence measurements
All microtiter plates were analysed using a Perkin Elmer
EnSpire plate reader with excitation at 360 nm and detecting
emission at 460 nm. Fluorescence measurements (RFU) were
converted to [AMC] concentrations based on an [AMC]-fluo-
rescence standard curve and all data analysis were performed
using GraphPad Prism.
Fluorescence-based preincubation inhibition experiments
Hydrolase activity of HDAC3-NCoR1 against substrate Ac-LGKac-
AMC was evaluated under varying concentrations of trifluoromethyl
ketone 4 and preincubation times. HDAC3 (1000 pg μL−1,
10 μL) was added to a solution of trifluoromethyl ketone 4
(30 μL total volume, 16.7 μM–167 pM, 10-fold dilution) at
37 °C (final concentrations 250 pg μL−1 and 12.5 μM–125 pM,
respectively) with preincubation times of 2 h, 1 h, 30 min,
15 min and 0 min, then a solution of Ac-LGKac-AMC (10 μL,
50 μM) was added to each well and the plate was incubated
for additional 30 min at 37 °C (final concentrations HDAC3:
200 pg μL−1, 4: 10 μM–100 pM, and Ac-LGKac-AMC: 10 μM,
respectively). Then a solution of trypsin (50 μL, 0.4 mg mL−1)
was added and the reaction mixture was developed for 15 min
before analysing fluorescence. The resulting data were analysed
to obtain residual enzymatic activity relative to control wells.
Fluorescence-based steady-state rate inhibition experiments
Hydrolase activities of HDACs against substrates Ac-LGKac-
AMC, Ac-LGKtfa-AMC and Ac-RHKacKac-AMC were evaluated
under varying concentrations of SAHA (1), TSA (2), and
trifluoromethyl ketone 4. The HDAC enzyme was incubated
with the relevant substrate, inhibitor, and trypsin in a total
volume of 100 μL of assay buffer (Buffer A, except for HDAC8,
where Buffer B was used), using the following concentrations:
HDAC1 (2500 pg μL−1), LGKac (20 μM), trypsin (3 ng μL
−1);
HDAC2 (4000 pg μL−1), LGKac (20 μM), trypsin (3 ng μL
−1);
HDAC3-NCoR1 (200 pg μL−1), LGKac (20 μM), trypsin (3 ng
μL−1); HDAC4 (50 pg μL−1), LGKtfa (50 μM), trypsin (5 ng
μL−1); HDAC6 (4000 pg μL−1), LGKac (20 μM), trypsin (3 ng
μL−1); HDAC7 (2.5 pg μL−1), LGKtfa (50 μM), trypsin (5 ng
μL−1); HDAC8 (5 pg μL−1), LGKtfa (200 μM), trypsin (3 ng
μL−1); HDAC8 (400 pg μL−1), RHKacKac (400 μM), trypsin (5 ng
μL−1). In situ fluorophore release was monitored immediately
by fluorescence readings recorded continuously every 10–15
seconds for 60 min at 25 °C. Using GraphPad Prism, back-
ground fluorescence was subtracted and the data were fitted
to the relevant equations ([P] = vst, or eqn (2)). Secondary
plots were then fitted to the relevant equations (eqn (1), (3)
or (4)) to obtain the desired kinetic parameters.
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